Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban and rivaroxaban transfer into breast milk study
2018-003852-19Phase 4Terminated
- Sponsor
- King's College London
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of apixaban and rivaroxaban in venous thromboembolism (VTE) (2 arms), sponsored by King's College London. Primary endpoint: Apixaban and metabolite concentrations in plasma and breast milk. Started Mar 2019; status: terminated.
02
Drugs
apixabanrivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2018-003852-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003852-19.